Biolase Company Profile (NASDAQ:BIOL)

About Biolase (NASDAQ:BIOL)

Biolase logoBIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BIOL
  • CUSIP: N/A
  • Web:
  • Market Cap: $41.03 million
  • Outstanding Shares: 75,976,000
Average Prices:
  • 50 Day Moving Avg: $0.61
  • 200 Day Moving Avg: $1.01
  • 52 Week Range: $0.48 - $1.98
  • Trailing P/E Ratio: N/A
  • P/E Growth: -0.1800
Sales & Book Value:
  • Annual Revenue: $50.48 million
  • Price / Sales: 0.85
  • Book Value: $0.33 per share
  • Price / Book: 1.70
  • EBIDTA: ($14,680,000.00)
  • Net Margins: -31.64%
  • Return on Equity: -64.44%
  • Return on Assets: -35.66%
  • Current Ratio: 2.21%
  • Quick Ratio: 1.23%
  • Average Volume: 143,783 shs.
  • Beta: 2.26
  • Short Ratio: 16.73

Frequently Asked Questions for Biolase (NASDAQ:BIOL)

What is Biolase's stock symbol?

Biolase trades on the NASDAQ under the ticker symbol "BIOL."

How were Biolase's earnings last quarter?

Biolase, Inc. (NASDAQ:BIOL) issued its quarterly earnings results on Monday, August, 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by $0.04. The business earned $12.61 million during the quarter. Biolase had a negative return on equity of 64.44% and a negative net margin of 31.64%. View Biolase's Earnings History.

When will Biolase make its next earnings announcement?

Biolase is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Biolase.

Where is Biolase's stock going? Where will Biolase's stock price be in 2017?

1 brokers have issued 12 month price objectives for Biolase's stock. Their forecasts range from $2.50 to $2.50. On average, they anticipate Biolase's share price to reach $2.50 in the next year. View Analyst Ratings for Biolase.

Who are some of Biolase's key competitors?

Who are Biolase's key executives?

Biolase's management team includes the folowing people:

  • Jonathan T. Lord M.D., Chairman of the Board
  • Harold C. Flynn Jr., President, Chief Executive Officer
  • Brendan O'Connell, Vice President - Finance and Corporate Controller
  • Holger Arens, Vice President, Managing Director of Europe, the Middle East and Africa
  • James D. Surek, Vice President - Sales, Americas
  • Michael Roux, Vice President of Marketing
  • Matthew Wilson, Vice President of Human Resources
  • Samuel B. Low, Vice President - Dental and Clinical Affairs, Chief Dental Officer
  • George W. Bickerstaff III, Director
  • Paul N. Clark, Director

Who owns Biolase stock?

Biolase's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.23%), Birchview Capital LP (1.90%), Granite Investment Partners LLC (1.41%), Trellus Management Company LLC (0.52%), Teton Advisors Inc. (0.50%) and California Public Employees Retirement System (0.18%). Company insiders that own Biolase stock include David C Dreyer, Jack W Schuler, Larry N Feinberg and Paul N Clark. View Institutional Ownership Trends for Biolase.

Who sold Biolase stock? Who is selling Biolase stock?

Biolase's stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Granite Investment Partners LLC and Princeton Capital Management Inc.. View Insider Buying and Selling for Biolase.

Who bought Biolase stock? Who is buying Biolase stock?

Biolase's stock was bought by a variety of institutional investors in the last quarter, including Trellus Management Company LLC. Company insiders that have bought Biolase stock in the last two years include David C Dreyer, Jack W Schuler, Larry N Feinberg and Paul N Clark. View Insider Buying and Selling for Biolase.

How do I buy Biolase stock?

Shares of Biolase can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biolase's stock price today?

One share of Biolase stock can currently be purchased for approximately $0.57.

MarketBeat Community Rating for Biolase (NASDAQ BIOL)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  57 (Vote Outperform)
Underperform Votes:  36 (Vote Underperform)
Total Votes:  93
MarketBeat's community ratings are surveys of what our community members think about Biolase and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Biolase (NASDAQ:BIOL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.50 (341.46% upside)

Analysts' Ratings History for Biolase (NASDAQ:BIOL)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/25/2017Singular ResearchInitiated CoverageBuy$2.50LowView Rating Details
(Data available from 9/21/2015 forward)


Earnings History for Biolase (NASDAQ:BIOL)
Earnings by Quarter for Biolase (NASDAQ:BIOL)
Earnings History by Quarter for Biolase (NASDAQ BIOL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.04)N/AView Earnings Details
8/7/2017Q2 2017($0.02)($0.06)$12.61 millionViewListenView Earnings Details
5/3/2017Q1 2017($0.03)($0.06)$10.87 millionViewListenView Earnings Details
3/8/2017Q4 2016$0.02($0.06)$13.76 millionViewListenView Earnings Details
11/8/2016Q316($0.02)($0.05)$12.40 million$13.20 millionViewListenView Earnings Details
5/9/2016Q116($0.03)($0.07)$11.90 million$11.00 millionViewN/AView Earnings Details
3/9/2016Q415($0.09)($0.04)$13.90 million$14.50 millionViewN/AView Earnings Details
11/4/2015Q315($0.08)($0.09)$1.50 million$11.20 millionViewN/AView Earnings Details
11/4/2014Q314($0.09)($0.08)$11.70 million$12.70 millionViewN/AView Earnings Details
8/7/2014Q214($0.08)($0.17)$12.97 million$10.20 millionViewN/AView Earnings Details
5/12/2014Q114($0.05)($0.11)$13.29 million$11.50 millionViewN/AView Earnings Details
3/5/2014Q413($0.04)($0.04)$15.67 million$15.20 millionViewN/AView Earnings Details
11/5/2013Q313($0.05)($0.10)$16.42 million$12.30 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.04)($0.06)$15.69 million$14.20 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.01)($0.06)$14.48 million$14.60 millionViewN/AView Earnings Details
3/6/2013Q4 2012$0.05$18.03 million$19.10 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Biolase (NASDAQ:BIOL)

No earnings estimates for this company have been tracked by


Dividend History for Biolase (NASDAQ:BIOL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Biolase (NASDAQ:BIOL)
Insider Ownership Percentage: 7.10%
Institutional Ownership Percentage: 37.34%
Insider Trades by Quarter for Biolase (NASDAQ:BIOL)
Institutional Ownership by Quarter for Biolase (NASDAQ:BIOL)
Insider Trades by Quarter for Biolase (NASDAQ:BIOL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/18/2016Jack W SchulerMajor ShareholderBuy500$0.80$400.00View SEC Filing  
2/17/2016Jack W SchulerMajor ShareholderBuy4,100$0.80$3,280.00View SEC Filing  
2/12/2016Jack W SchulerMajor ShareholderBuy19,080$0.76$14,500.80View SEC Filing  
2/10/2016Jack W SchulerMajor ShareholderBuy67,213$0.78$52,426.14View SEC Filing  
1/25/2016Jack W SchulerMajor ShareholderBuy1,400$0.80$1,120.00View SEC Filing  
1/22/2016Jack W SchulerMajor ShareholderBuy6,670$0.78$5,202.60View SEC Filing  
1/20/2016Jack W SchulerMajor ShareholderBuy24,200$0.75$18,150.00View SEC Filing  
12/28/2015Jack W SchulerMajor ShareholderBuy18,350$0.79$14,496.50View SEC Filing  
12/24/2015Jack W SchulerMajor ShareholderBuy41,900$0.76$31,844.00View SEC Filing  
12/22/2015Jack W SchulerMajor ShareholderBuy87,200$0.74$64,528.00View SEC Filing  
12/21/2015Jack W SchulerMajor ShareholderBuy127,892$0.73$93,361.16View SEC Filing  
12/17/2015Jack W SchulerMajor ShareholderBuy34,158$0.70$23,910.60View SEC Filing  
11/11/2015Larry N FeinbergMajor ShareholderBuy54,800$0.79$43,292.00View SEC Filing  
11/10/2015Paul N ClarkDirectorBuy134,579$0.75$100,934.25View SEC Filing  
9/24/2015David C DreyerCFOBuy5,000$1.20$6,000.00View SEC Filing  
9/22/2015David C DreyerCFOBuy5,000$1.37$6,850.00View SEC Filing  
9/17/2015David C DreyerCFOBuy10,000$1.45$14,500.00View SEC Filing  
11/3/2014Jeffrey M NugentCEOBuy40,465$2.39$96,711.35View SEC Filing  
11/3/2014Jonathan T Md LordDirectorBuy101,163$2.39$241,779.57View SEC Filing  
11/3/2014Larry N FeinbergMajor ShareholderBuy2,067,979$2.39$4,942,469.81View SEC Filing  
7/22/2014Alexander K ArrowCOOBuy7,812$1.92$14,999.04View SEC Filing  
7/22/2014Frederick D FurryCFOBuy13,020$1.92$24,998.40View SEC Filing  
7/22/2014Jeffrey M NugentCEOBuy52,083$1.92$99,999.36View SEC Filing  
7/22/2014Paul N ClarkDirectorBuy520,833$1.92$999,999.36View SEC Filing  
7/18/2014Larry N FeinbergMajor ShareholderBuy2,270,836$1.92$4,360,005.12View SEC Filing  
2/12/2014Larry N FeinbergMajor ShareholderBuy2,035,033$2.57$5,230,034.81View SEC Filing  
1/31/2014Larry Feinbergmajor shareholderBuy30,798$2.45$75,455.10View SEC Filing  
12/19/2013Larry Feinbergmajor shareholderBuy340,000$1.80$612,000.00View SEC Filing  
12/17/2013Larry Feinbergmajor shareholderBuy150,400$1.87$281,248.00View SEC Filing  
8/23/2012Frederick D FurryCFOBuy5,075$1.64$8,323.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Biolase (NASDAQ:BIOL)
Latest Headlines for Biolase (NASDAQ:BIOL)
DateHeadline logoETFs with exposure to BIOLASE, Inc. : September 6, 2017 - September 5 at 11:15 PM logoBIOLASE Names Jonathan T. Lord Chairman of the Board - September 5 at 6:10 PM logoLeMaitre Vascular (LMAT) and Biolase (BIOL) Head-To-Head Review - September 2 at 4:10 PM logoETFs with exposure to BIOLASE, Inc. : August 25, 2017 - August 25 at 6:18 PM logoGlobsl $10 Billion Dental Diagnostics & Surgical Equipments Products Markets, 2022 - August 17 at 5:55 PM logoBIOLASE, Inc. :BIOL-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017 - August 16 at 5:05 PM logoGlobal Dental Diagnostics & Surgical Equipments Market, Company Analysis & Forecast to 2024 - August 14 at 9:59 PM logoContrasting Dextera Surgical (DXTR) and Biolase (NASDAQ:BIOL) - August 11 at 3:08 PM logoEdited Transcript of BIOL earnings conference call or presentation 7-Aug-17 8:30pm GMT - August 8 at 9:42 PM logoETFs with exposure to BIOLASE, Inc. : August 8, 2017 - August 8 at 4:20 PM logoBiolase, Inc. (BIOL) Releases Earnings Results, Misses Estimates By $0.04 EPS - August 8 at 12:28 PM logoBiolase reports 2Q loss - August 7 at 10:05 PM logoBIOLASE Reports 2017 Second Quarter and Six-Month Results - August 7 at 5:04 PM logoBiolase (NASDAQ:BIOL) & Agilent Technologies (A) Head-To-Head Comparison - August 2 at 8:10 AM logoBIOLASE® to Host 2017 Second Quarter Financial Results Conference Call on August 7 - July 31 at 4:34 PM logoBRIEF-Biolase Inc files for resale of up to 12 million shares - July 22 at 9:30 PM logoETFs with exposure to BIOLASE, Inc. : July 13, 2017 - July 13 at 5:34 PM logoForm 4 BIOLASE, INC For: Jun 30 Filed by: MOLL FREDERIC H - July 4 at 8:26 PM logoForm 4 BIOLASE, INC For: Jun 30 Filed by: CLARK PAUL N - July 4 at 2:43 AM logoETFs with exposure to BIOLASE, Inc. : June 26, 2017 - June 26 at 4:31 PM logoMedical Lasers Market Size is Projected to be Around $13 Billion by 2025: Crystal Market Research - June 20 at 4:38 PM logoBIOLASE (BIOL) Presents At 7th Annual LD Micro Invitational Conference - Slideshow - June 8 at 4:44 PM logoReviewing EnteroMedics (ETRM) and BIOLASE (BIOL) - June 6 at 2:06 PM logoBIOLASE to Present at the 7th Annual LD Micro Invitational - May 31 at 10:35 AM logoETFs with exposure to BIOLASE, Inc. : May 22, 2017 - May 22 at 3:52 PM logoShort Interest in BIOLASE Inc (BIOL) Drops By 1.4% - May 13 at 7:08 PM logoETFs with exposure to BIOLASE, Inc. : May 11, 2017 - May 11 at 4:28 PM logoBIOLASE, Inc. :BIOL-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 - May 9 at 3:56 PM logoBIOLASE Announces Management Change - May 5 at 3:56 PM logoBIOLASE Inc (BIOL) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS - May 4 at 9:00 PM logoEdited Transcript of BIOL earnings conference call or presentation 3-May-17 8:30pm GMT - May 4 at 4:03 PM logoBIOLASE Reports 2017 First Quarter Results - May 3 at 6:14 PM logoBiolase reports 1Q loss - May 3 at 6:05 PM logoSomewhat Favorable Media Coverage Somewhat Likely to Impact BIOLASE (BIOL) Share Price - May 2 at 11:26 PM logoBIOLASE Inc (BIOL) Scheduled to Post Quarterly Earnings on Wednesday - May 1 at 1:18 PM logoBIOLASE (BIOL) Earning Somewhat Favorable News Coverage, Report Finds - April 26 at 2:32 PM logoBIOLASE® to Host 2017 First Quarter Financial Results Conference Call on May 3 - April 26 at 12:27 PM logoBIOLASE Inc (BIOL) Coverage Initiated at Singular Research - April 25 at 3:06 PM logoForm 4 BIOLASE, INC For: Apr 18 Filed by: LORD JONATHAN T MD - April 19 at 9:14 PM logoBIOLASE (BIOL) Earning Somewhat Favorable Media Coverage, Report Finds - April 17 at 5:25 PM logoBIOLASE (BIOL) Earning Positive News Coverage, Report Shows - April 14 at 5:40 PM logoBIOLASE to Raise $10.5 Million from Institutional and Individual Investors in a Private Placement - April 13 at 4:03 PM logoREGISTER TODAY: Multidisciplinary Treatment Solutions for Peri-Implantitis Symposium - April 7 at 3:52 PM logoBIOLASE to Showcase Two New Game-Changing Products at International Dental Show in Cologne - March 20 at 11:08 AM logoBIOLASE, INC Financials - March 16 at 3:22 PM logoBIOLASE Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) - March 14 at 8:41 AM logoBIOLASE Names James D. Surek Vice President Sales, Americas - March 13 at 11:12 AM logoBIOLASE, INC Files SEC form 10-K, Annual Report - March 10 at 4:44 PM logoBIOLASE to Present at the 29th Annual ROTH Conference - March 9 at 4:27 PM logoBRIEF-Biolase Q4 loss per share $0.07 - March 9 at 2:42 AM



Biolase (BIOL) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by Staff